488 related articles for article (PubMed ID: 28447417)
21. [The frontline of TMA management].
Saito K; Matsumoto M
Rinsho Ketsueki; 2022; 63(5):463-470. PubMed ID: 35662172
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms in thrombotic thrombocytopenic purpura.
Tsai HM
Semin Thromb Hemost; 2004 Oct; 30(5):549-57. PubMed ID: 15497097
[TBL] [Abstract][Full Text] [Related]
23. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
Pecoraro C; Ferretti AV; Rurali E; Galbusera M; Noris M; Remuzzi G
Am J Kidney Dis; 2015 Dec; 66(6):1067-70. PubMed ID: 26409664
[TBL] [Abstract][Full Text] [Related]
25. The molecular biology of thrombotic microangiopathy.
Tsai HM
Kidney Int; 2006 Jul; 70(1):16-23. PubMed ID: 16760911
[TBL] [Abstract][Full Text] [Related]
26. [Complement-mediated hemolytic uremic syndrome: a diagnostic approach].
Wieliczko M; Twardowska-Kawalec M
Wiad Lek; 2019; 72(11 cz 2):2239-2244. PubMed ID: 31860845
[TBL] [Abstract][Full Text] [Related]
27. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).
Licht C; Stapenhorst L; Simon T; Budde U; Schneppenheim R; Hoppe B
Kidney Int; 2004 Sep; 66(3):955-8. PubMed ID: 15327386
[TBL] [Abstract][Full Text] [Related]
28. Thrombotic microangiopathies: from animal models to human disease and cure.
Caprioli J; Remuzzi G; Noris M
Contrib Nephrol; 2011; 169():337-350. PubMed ID: 21252531
[TBL] [Abstract][Full Text] [Related]
29. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008.
Fujimura Y; Matsumoto M
Intern Med; 2010; 49(1):7-15. PubMed ID: 20045995
[TBL] [Abstract][Full Text] [Related]
30. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
[TBL] [Abstract][Full Text] [Related]
31. [Diagnosis and treatment of microangiopathic hemolytic anemia].
Morishita E
Rinsho Ketsueki; 2015 Jul; 56(7):795-806. PubMed ID: 26251142
[TBL] [Abstract][Full Text] [Related]
32. Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review.
McFarlane PA; Bitzan M; Broome C; Baran D; Garland J; Girard LP; Grewal K; Lapeyraque AL; Patriquin CJ; Pavenski K; Licht C
Can J Kidney Health Dis; 2021; 8():20543581211008707. PubMed ID: 33996107
[TBL] [Abstract][Full Text] [Related]
33. The role of von Willebrand factor in thrombotic microangiopathy.
Noone DG; Riedl M; Licht C
Pediatr Nephrol; 2018 Aug; 33(8):1297-1307. PubMed ID: 28748411
[TBL] [Abstract][Full Text] [Related]
34. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis.
Laurence J
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 17):1-12. PubMed ID: 23187605
[TBL] [Abstract][Full Text] [Related]
35. [Pathophysiology of thrombotic microangiopathies: current understanding].
Coppo P; Veyradier A; Durey MA; Fremeaux-Bacchi V; Scrobohaci ML; Amesland F; Bussel A
Ann Med Interne (Paris); 2002 May; 153(3):153-66. PubMed ID: 12218898
[TBL] [Abstract][Full Text] [Related]
36. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.
Tsai HM
Transfus Med Rev; 2014 Oct; 28(4):187-97. PubMed ID: 25280590
[TBL] [Abstract][Full Text] [Related]
37. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura.
Noris M; Remuzzi G
Semin Nephrol; 2010 Jul; 30(4):395-408. PubMed ID: 20807612
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis and prognosis of thrombotic microangiopathy.
Nangaku M; Nishi H; Fujita T
Clin Exp Nephrol; 2007 Jun; 11(2):107-114. PubMed ID: 17593509
[TBL] [Abstract][Full Text] [Related]
39. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.
Kremer Hovinga JA; Studt JD; Alberio L; Lämmle B
Semin Hematol; 2004 Jan; 41(1):75-82. PubMed ID: 14727262
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of thrombotic microangiopathies.
Zheng XL; Sadler JE
Annu Rev Pathol; 2008; 3():249-77. PubMed ID: 18215115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
